Pancreatic cancer is a mass (tumor mass) made up of cancerous cells in the pancreas. There are several types of pancreatic cancer, but ductal adenocarcinoma, which originates from pancreatic ductal cells, accounts for about 90%. The cause of pancreatic cancer has not yet been clearly identified and compared to other cancers, the pre-cancerous lesions that act as the cause of cancer are also not clear. Factors likely to cause pancreatic cancer include age over 45 years old, smoking history, history of head and neck, lung, and bladder cancer, long-term diabetes, and intake of fatty foods. Recently, it has been reported that the incidence of pancreatic cancer increases in chronic pancreatitis and some genetic diseases.

• In all-stage combined-pancreatic cancer patients, the 5-year survival rate is 9%.
• FOLFIRINOX and Gemcitabine/NAB-paclitaxel are administered as the first-line treatment for pancreatic cancer, but still, there are patients who are refractory to the treatment due to its cytotoxic effects to both normal and cancer cells.
• Immunohistochemistry analysis of Pancreatic 60 pancreatic cancer patients revealed that 55 % of the patients are characterized with high expression of HASPIN.

• ① Suppression of mitosis via inhibition of HASPIN
• ② Impaired mitosis leads to cell apoptosis

• Compound annual growth rate: 7.43 % (2022~2027)
• Global market size for pancreatic cancer: reaching 5,656.58m$ by 2027